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232 A new method for monitoring spirometry − implications for
cystic ﬁbrosis care
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Introduction: Accurate serial assessment of FEV1 is essential to help the clinician
combat deterioration in CF patients, and spirometry equipment must be capable
of reliable and reproducible measurements. Traditional equipment (e.g. Vitalograph
2120) uses reusable ﬂow sensors (i.e. pneumotachograph) which require disposable
ﬁlters, thereby increasing equipment dead-space and resistance. Newer technology
(Spirostik™) uses disposable ﬂow sensors which do not require ﬁlters, reducing
dead-space and airﬂow resistance. We have recently switched over to this new
technique and have compared its effect on the FEV1 measurement in our adult CF
patients.
Method: 85 consecutive adult CF patients (mean age 28 [range 17−53], mean FEV1
59% [12–120], 46 male) performed FVC manoeuvres (measuring FEV1) according
to ATS/ERS guidelines, on Spirostik™ and Vitalograph 2120. Student’s paired t test
was used for statistical analysis.
Results: Patients found the new device easier to use, since it gave them more
feedback during the manoeuvre. Spirostik™ recorded on average 9.7% higher FEV1
than Vitalograph 2120 (mean FEV1 2.41 litres [SD 1.00, range 0.8–5.14] versus
2.18 [0.89, 0.6–4.32], P< 0.001). Overall, 76 patients (91%) had higher values on
Spirostik™ compared to 2120.
Conclusions: This potentially more accurate measure of spirometry has increased
the average value of FEV1 in our patients signiﬁcantly. This not only has implica-
tions for clinical practice in that we are now having to “recalibrate” our views of
individual patient’s clinical progress, but it will also alter the value of data sent to
national registries.
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Background: Allergies are commonly found in children. Asthma and allergic
bronchopulmonary aspergillosis (ABPA) are important co-morbidities associated
with cystic ﬁbrosis (CF). The aim of the paper was to evaluate the frequency of
allergic reactions, with respiratory or cutaneous manifestations among children with
cystic ﬁbrosis.
Methods: One hundred and twenty-four children with CF were evaluated. Obser-
vational study was designed, using for retrospective analysis data records from our
CF Centre. Frequency of allergic rhinitis, asthma, aspergillosis was evaluated, also
food allergies and antibiotics allergic reaction. Skin prick test and IgE speciﬁc tests
were used.
Results: Allergic rhinitis was diagnosed in 12 patients (9.67%). A small percentage
7.25% (9 patients) were diagnosed with associated asthma. Thirteen children
(10.4%) were diagnosed with sensitization to ABPA, 3 of them had aspergillosis,
with rapid decline of lung function. Skin allergies were much frequently associated,
over 50% of CF children had at list one dermatitis episode, more than 70% of those
IgE-speciﬁc positive. Fortunately, documented antibiotic allergy was found in only
2.41% of patients.
Conclusion: Although respiratory allergies are increasing in frequency, they are not
signiﬁcant co morbidity in our CF patients. Predominant clinical feature of allergic
reaction was cutaneous. What features are protective for development of respiratory
allergies remains to be assessed.
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Aim: To investigate the activity and levels of proteolytic enzymes and activity of
anti-proteolysis in children with bronchial pathology (BP) and different levels of
lung tissue ﬁbrosis (FLT).
Objectives and Methods: 184 patients with BP and cystic ﬁbrosis (CF) were
enrolled. Neutrophils-enriched plasma was placed in test tubes with Lithium
heparin. To determine the levels of matrix metalloproteinase-7 (MMP-7), neutrophil
elastase (NE) and the activity of anti-elastase (AE), immuno-enzymes method was
used.
Results: The NE level in patients not affected by FLT was 25% lower than that
in patients with FLT, but due to data variations, the difference was not statistically
signiﬁcant. In all patients, the levels of NE were from 3.4 to 7.2 times higher than
those in the control group (CG, n = 30) (p< 0.01–0.001). The activity of AE in
non-FLT patients with lung pathology did not differ from the CG. FLT stimulated
the activity of AE. In patients at the initial stages of ﬁbrosis (n = 15), the NE
activity was 1.5 times lower than in children with diffusive pneumosclerosis (n = 9)
(p< 0.05). The MMP-7 level in BP children not affected by FLT was higher than
that in CG (p< 0.001). Across the board, the FLT group showed almost twofold
MMP-7 content comparing to patients with no ﬁbrosis.
With the increase of ﬁbrosis, the MMP-7 level went up, reaching 12.5±2.0 ng/mml
for children with diffusive pneumosclerosis; for those with localized FLT, it was
5.4±0.58 ng/mml, and for patients without ﬁbrosis it was 3.45±0.12 ng/mml.
Conclusion: Patients with diffusive pneumosclerosis, the majority of whom were
children with CF, demonstrated high levels of MMP-7 and AE activity.
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Identiﬁcation of bacterial pathogens is paramount for prompt and effective treatment
of respiratory exacerbations in children with cystic ﬁbrosis (CF). This can be a
challenge in non expectorating patients as reliability of cough swabs (CS) is poor.
More recently, cough plates (CP) have shown potential as an alternative method.
Aim: To ascertain the effectiveness of CP as compared to CS and to assess the
impact of cough strength on efﬁcacy of CP.
Method: Non expectorating children with CF aged 3−16 years were recruited.
Baseline data was recorded and peak cough ﬂow (PCF) measured. Following this,
specimens were taken with CP and a CS in randomised order. This procedure was
repeated on up to 4 clinic visits to obtain multiple measurements.
Results: 95 subjects participated, mean age 8.8±4.1 years, 45 males. Mean
baseline % predicted FEV1 was 90.8±18. PCF was recorded in 76 patients,
mean 294.7±128.7. 324 sets of specimens were collected. Overall, pathogens were
isolated in 18.2% of CS and 8% of CP p< 0.05. Numbers for individual visits
were as follows: visit 1: CS 17.9%, CP 10.5% (p = 0.065), visit 2: CS 26.7%, CP
7% (p< 0.05), visit 3: CS 12.8%, CP 9% (p = 0.45), visit 4: CS 14%, CP 4.6%
(p = 0.07). Agreement between the two specimens occurred in only 5.5% of cases.
6 CP isolated pathogens when the CS was negative whilst 40 CS were positive with
a corresponding negative CP. Cough strength increased with age and pathogens
were more likely to be isolated on the CP from older children. 84% of subjects
preferred the CP.
Conclusion: CP are less effective than CS in the identiﬁcation of respiratory
pathogens in children with CF.
